MOTS-c and the work of moving
A grip test gives this literature a useful starting point. The explanation leads into muscle, energy sensing and a signal encoded in mitochondrial DNA.
Running, grip strength and gait
The physical-decline study by Reynolds and colleagues tested mice at 2, 12 and 22 months of age. Administered MOTS-c improved physical performance across those ages. In the aged group, 22 to 23.5 months, treadmill running capacity improved with a reported P value of 0.000002, alongside improvements in grip strength and gait.
The same work showed that exercise induces the body's own MOTS-c in skeletal muscle and circulation. Put those observations together and “exercise mimetic” becomes an understandable hypothesis. It still needs a test of the proposed substitution. Human benefit from administering the peptide remains unestablished.
I'd put walking ability near the top of the wish list for an ageing trial. The tests appeal to my ordinary ambitions; their unanswered human counterpart is frustrating.
A peptide encoded in mitochondrial DNA
MOTS-c is a chain of 16 amino acids encoded within MT-RNR1, the mitochondrial 12S ribosomal RNA gene. Mitochondria supply energy to cells and carry their own small genome; in this case, that genome also encodes a signal that reaches beyond the mitochondrion. The MOTS-c review by Wan and colleagues brings those strands of the biology together.
One proposed route to its metabolic effects runs through inhibition of the folate cycle and de novo purine synthesis. This raises AICAR, which activates AMPK, an enzyme involved in sensing an energy shortage. The downstream effects on glucose handling and insulin sensitivity have been studied chiefly in muscle and preclinical models.
Under metabolic stress, MOTS-c also moves into the nucleus and regulates stress-responsive genes in human and mouse cells. That work linked the response to AMPK and the transcription factor NRF2. The reversal delights me: a signal encoded by the energy-supplying compartment participates in nuclear gene regulation. Calling it an energy booster loses that interesting specificity.
CK2 and muscle wasting
The 2024 CK2 paper added a direct binding partner. MOTS-c bound and activated casein kinase 2 in cell-free assays; work in young, aged, high-fat-diet and immobilised mice connected tissue-specific CK2 modulation with muscle glucose uptake and prevention of atrophy, or muscle wasting. CK2 activity rose in muscle and was suppressed in fat.
The tissue difference matters to me. A slogan about “activating” a pathway would miss the opposite responses in those tissues. This is an account of regulation with a particular target, and it remains an account built from assays and mice.
The haemodialysis cohort
In the prospective study of 94 chronic haemodialysis patients, the researchers measured circulating MOTS-c and followed a combined outcome of all-cause mortality and non-fatal cardiovascular events. Median follow-up was 26.5 months. The reported Cox hazard ratio was 1.004, p=0.05; adding MOTS-c to the risk model changed the ROC area under the curve from 0.727 to 0.743.
Those figures describe prognostic information from the patients' own circulating peptide. Nobody was assigned MOTS-c treatment. Prediction deserves follow-up here; the practical question about giving the peptide remains open. Dialysis patients are also a specific population; the result cannot simply stand in for healthy older adults.
Human safety and research status
No completed human interventional efficacy trial establishes a benefit from exogenous MOTS-c, and there is no validated human half-life, bioavailability or dose-response. A controlled human safety profile is missing too. The absence of such a profile leaves harm insufficiently characterised.
MOTS-c is not FDA-approved for any use. Material labelled for laboratory research is still sold, with no human-consumption purpose or pharmaceutical controls for purity, identity and sterility. Anti-doping authorities treat MOTS-c as prohibited in elite sport, where its use can bring sanctions.
For the moment, the most concrete achievement in this story is improved physical performance in mice. Until a human trial measures function alongside adverse events, my enthusiasm has too little to work with.